Korean J Helicobacter  Up Gastrointest Res Search


Korean J Helicobacter  Up Gastrointest Res > Volume 16(4); 2016 > Article
The Korean Journal of Helicobacter  and Upper Gastrointestinal Research 2016;16(4):204-214.
DOI: https://doi.org/10.7704/kjhugr.2016.16.4.204    Published online December 10, 2016.
The Effect of Esomeprazole 40 mg Single Therapy in Patients with Non-Erosive Reflux Disease Who Are Resistant to Standard-Dose Proton Pump Inhibitor Therapy: An Open-Label Multicenter Study
Jae Kyu Sung, Tae Ho Kim, Su Jin Hong, Sang Gyun Kim, Hwoon Yong Jung, Yong Chan Lee, Byung Ik Jang, Soo Heon Park
1Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
2Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. psheon5132@naver.com
3Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.
4Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
5Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea.
6Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
7Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
표준용량 양성자펌프억제제에 반응을 보이지 않는 비미란성 역류질환 환자에서 Esomeprazole 40 mg 단일 요법의 유효성: 다기관 공개 연구
성재규, 김태호1, 홍수진2, 김상균3, 정훈용4, 이용찬5, 장병익6, 박수헌1
충남대학교 의과대학 내과학교실, 가톨릭대학교 의과대학 내과학교실1, 순천향대학교 의과대학 내과학교실2, 서울대학교 의과대학 내과학교실3, 울산대학교 의과대학 내과학교실4, 연세대학교 의과대학 내과학교실5, 영남대학교 의과대학 내과학교실6
Received: 31 October 2016   • Accepted: 6 December 2016
Despite the efficacy of proton pump inhibitor (PPI) treatment, a considerable number of patients with non-erosive reflux disease (NERD) are resistant to treatment with a PPI at the standard dose. In these patients, doubling the dose of PPI is one of the potential therapeutic strategies. However, only few studies support this therapeutic strategy. The aim of this study was to assess the efficacy and safety of 40 mg esomeprazole once daily in patients with persistent symptoms of NERD despite standard daily PPI therapy. MATERIALS AND METHODS: A total of 92 patients with NERD who had persistent symptoms of NERD despite standard dose (half dose) of PPI for more than 4 weeks, were enrolled in this multicenter (eight centers) open-label study. Efficacy and safety of a daily dose of 40 mg esomeprazole were evaluated after 4 weeks in all the patients. RESULTS: The sum score of two symptoms (heartburn and regurgitation) decreased significantly from 72.51 to 32.55 after 4 weeks of treatment (P<0.001). The percentage of patients with ≥50% improvement in symptom score (heartburn+acid regurgitation), during the study period was 66.7%. Patients with severe symptoms at baseline had significantly higher symptom improvement rate in comparison to patients who had milder symptoms. Adverse effects related to the treatment were reported by 3 (3.3%) patients. CONCLUSIONS: Esomeprazole 40 mg once daily is an effective and safe strategy to treat NERD patients with persistent symptoms despite standard daily PPI therapy.
Key Words: Gastroesophageal reflux; Esomeprazole; Proton pump inhibitors
Share :
Facebook Twitter Linked In Google+ Line it
METRICS Graph View
  • 0 Crossref
  • 1,977 View
  • 38 Download
Related articles in Korean J Helicobacter Up Gastrointest Res

Editorial Office
Lotte Gold Rose II Room 917, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-717-5543    Fax: +82-2-565-9947    E-mail: helicojournal@smileml.com                

Copyright © 2024 by Korean College of Helicobacter and Upper Gastrointestinal Research.

Developed in M2PI

Close layer
prev next